Compare NYAX & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYAX | DVAX |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | 2004 |
| Metric | NYAX | DVAX |
|---|---|---|
| Price | $55.34 | $15.48 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $47.50 | $26.50 |
| AVG Volume (30 Days) | 9.0K | ★ 2.9M |
| Earning Date | 03-03-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $369,938,000.00 | $330,514,000.00 |
| Revenue This Year | $29.95 | $24.63 |
| Revenue Next Year | $23.27 | $15.85 |
| P/E Ratio | $84.78 | ★ N/A |
| Revenue Growth | ★ 26.84 | 26.73 |
| 52 Week Low | $32.38 | $9.20 |
| 52 Week High | $60.77 | $15.73 |
| Indicator | NYAX | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 75.83 |
| Support Level | $53.79 | $15.46 |
| Resistance Level | $59.84 | $15.73 |
| Average True Range (ATR) | 1.03 | 0.06 |
| MACD | -0.77 | -0.17 |
| Stochastic Oscillator | 34.98 | 6.52 |
Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It provides consumers with digital, cashless payments, and connected commerce experiences, enhancing consumer conversion and loyalty. Its platform addresses the entire unattended commerce value chain, including a payments infrastructure, a commerce software suite, a consumer engagement platform, and integrated POS devices. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.